011 Stabilisation of SR leak in heart failure after SERCA2A gene therapy. (22nd September 2015)

• Record Type: Journal Article
• Authors: Lyon, A R; Bannister, M L; Coward, E; Dubb, S S; Garcia, E; Kohlbrenner, E; Hajjar, R J; Harding, S E; Macleod, K M
• Is Part Of: Heart. Volume 96(2010)Supplement 1
• Page Start: A10
• Page End: A10
• Publication Date: 2015-09-22
• Subjects: SERCA2a gene therapy -- SR calcium leak -- arrhythmias; Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/hrt.2010.195941.11
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) gene therapy improves mechanical function in heart failure, and is under evaluation in a clinical trial. Restoration of sarcoplasmic reticulum (SR) Ca 2+ levels by SERCA2a gene therapy may alter SR Ca 2+ leak in the failing heart. A critical question is whether SERCA2a predisposes to increased SR leak and cellular triggered activity by restoring SR Ca 2+ levels? Methods: Cardiomyocytes were studied isolated from rats with heart failure 4–6 weeks post in vivo AAV9SERCA (2×1011 drp) gene transfer (HF+S). Cells from untreated failing (HF) and non failing (NF) hearts served as controls. Spontaneous Ca 2+ spark generation was measured in fluo4-loaded cells by scanning confocal microscopy during a quiescent 30 s period after baseline stimulation. Field stimulated calcium transients were measured at 0.5 Hz, followed by caffeine application to measure SR Ca 2+ load. The ratio of sparks:SR load and Leak Index reflecting total SR Ca 2+ leak (spark frequency × amplitude × width × duration) were calculated. Baseline and isoproterenol (ISO)-induced triggered activity were measured in parallel cell studies, and ryanodine receptor (RyR) phosphorylation was measured. Results: SERCA2a gene transfer normalised SR Ca 2+ load of failing myocytes (HF+S 5.86±0.64 vs HF 4.24±0.32 p<0.05 (NF 5.34±0.38)) with recovery of Ca 2+ transient relaxation kinetics (R50 (ms): HF+S 174±14, HF 292±42, NF 179±23 p<0.01). Spark frequency was unchanged between HF+S (2.9±0.4) and HF (2.5±0.4), with both significantly higher than NF (1.2±0.2 p<0.01). Interestingly spark amplitude was significantly reduced in HF+S compared with HF, with no change in spark decay kinetics, leading to a significant reduction in total SR leak. Leak index: NF234±76, HF 1630±358, HF+S 683±192 (p<0.05). Total RyR was reduced by 20% in failing hearts, with a significant increase in the proportion of RyR-P2809 and RyR-P2815 compared to non-failing controls (p<0.05). These RyR-P and total RyR changes were reversed to normal after SERCA2a gene transfer to failing hearts. Despite increased SR content and unaltered spark frequency, myocytes from HF+S hearts were more stable in vitro, with significantly fewer basal and ISO-induced aftercontractions compared to HF (p<0.05). Conclusion: SERCA2a gene therapy reduced total SR Ca 2+ leak of failing myocytes whilst concurrently increasing SR Ca 2+ load to normal levels. Leak reduction was dependent upon altered spark characteristics as spontaneous spark frequency was unchanged, and reduced RyR phosphorylation supports resetting of SR Ca 2+ leak threshold after SERCA2a gene transfer. SERCA2a gene therapy reduced ISO-induced triggered activity in vitro and ISO-induced arrhythmias in vivo, and may represent a novel antiarrhythmic strategy in heart failure.